Record Q2 with 10%+ pump shipment growth, 6% sales increase, and 57% gross margin. Pharmacy channel adoption reached 10% of U.S. sales, with strong international growth and new technology launches. Guidance for 2026 reaffirmed, with highest margins expected in Q4.Based on Tandem Diabetes Care, Inc…
Diabetes technology company Tandem Diabetes Care NASDAQ:TNDMmet Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $254.6 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.08 billion at the midpoint. Its GAAP…
Tandem Diabetes Care Inc reported results for the 2026 quarter with revenue of $254.56M, an improvement from $240.68M a year earlier, and a smaller net loss of ($21.17M) versus ($52.4M) in the prior-year quarter; diluted loss per share narrowed to ($0.31) from ($0.78).Financial Highlights¹ Reported…
Diabetes technology company Tandem Diabetes Care NASDAQ:TNDMwill be announcing earnings results this Thursday after market close. Here’s what you need to know.Tandem Diabetes beat analysts’ revenue expectations last quarter, reporting revenues of $247.2 million, up 5.5% year on year. It was a very…
